Georgia Capital (FRA:2IX) Research & Development: €0.0 Mil (TTM As of Dec. 2025)


FRA:2IX Georgia Capital PLC FRA:2IX
64 GF Score
Price €45.40
GF Value €48.42
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Georgia Capital Research & Development?

Georgia Capital FRA:2IX -3.81% 64 Research & Development is €0.0 Mil as of Dec. 2025. GuruFocus rates FRA:2IX with a GF Score™ of 64/100 and a GF Value™ of €48.42 (Fairly Valued). The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Georgia Capital's Research & Development for the six months ended in Dec. 2025 was €0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was €0.0 Mil.

Georgia Capital  (FRA:2IX) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Georgia Capital Research & Development Related Terms

Georgia Capital Research & Development Historical Data

* Premium members only.

The historical data trend for Georgia Capital's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Georgia Capital Research & Development Chart

Georgia Capital Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Georgia Capital Semi-Annual Data
Dec15 Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:2IX
64GF Score
Georgia Capital PLC FRA:2IX
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Georgia Capital Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0.0 Mil mean?
Georgia Capital (FRA:2IX) has a Research & Development of €0.0 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Georgia Capital and its competitors.
Is Georgia Capital's Research & Development too high?
Georgia Capital's current Research & Development is €0.0 Mil. Overall, Georgia Capital has a GF Score™ of 64/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Georgia Capital's Research & Development compare to FRHC?
Georgia Capital's Research & Development of €0.0 Mil can be compared against companies in the Diversified Financial Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Diversified Financial Services company?
A good Research & Development depends on the Diversified Financial Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Georgia Capital and its competitors. Georgia Capital's current Research & Development is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Georgia Capital stock overvalued right now?
Based on GuruFocus' analysis, Georgia Capital (FRA:2IX) is currently considered Fairly Valued. The stock's GF Value™ is €48.42, compared to a current price of €45.40 — trading 6.2% below its estimated fair value. The current Research & Development is €0.0 Mil. Georgia Capital's overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Georgia Capital (FRA:2IX), the current Research & Development is €0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Georgia Capital (FRA:2IX) Overvalued in 2026?

Based on GuruFocus' analysis, Georgia Capital stock appears to be undervalued. The current stock price of €45.40 is trading 6.2% below its estimated GF Value™ of €48.42. GuruFocus considers Georgia Capital to be Fairly Valued.

Key valuation signals for FRA:2IX:

  • Research & Development: €0.0 Mil
  • GF Value™: €48.42 vs. price of €45.40 (6.2% below fair value)
  • GF Score™: 64/100 with 3 warning signs

No single metric tells the full story. See the FRA:2IX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Georgia Capital Business Description

Other Exchanges GRGCF:USACGEOl:UKCGEO:UK
Address 19th Floor 51 Lime Street, London, GBR, EC3M 7DQ
Georgia Capital PLC is focused on buying, building and developing businesses in Georgia and monetising investments as it matures. The company currently has the following private large portfolio businesses (i) a retail (pharmacy) business, (ii) an insurance business (P&C and medical insurance), and (iii) a healthcare services business (hospitals and clinics and diagnostics). The company's operating segments are: listed and observable portfolio companies, private large portfolio companies, private emerging and other portfolio companies, and corporate centre.
64GF Score

Get the complete analysis for FRA:2IX

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€45.40
Price
€48.42
GF Value